DexCom

YTD

ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

CEO

Jacob S. Leach

CEOJacob S. Leach

Employees

11,100

Employees11,100

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1999

Founded1999

Employees

11,100

Employees11,100

DXCM Key Statistics

Market cap

32.99B

Market cap32.99B

Price-Earnings ratio

32.52

Price-Earnings ratio32.52

Dividend yield

—

Dividend yield—

Average volume

6.06M

Average volume6.06M

High today

$88.96

High today$88.96

Low today

$84.24

Low today$84.24

Open price

$85.07

Open price$85.07

Volume

5.25M

Volume5.25M

52 Week high

$92.59

52 Week high$92.59

52 Week low

$54.11

52 Week low$54.11

Stock Snapshot

With a market cap of 32.99B, DexCom(DXCM) trades at $88.28. The stock has a price-to-earnings ratio of 32.52.

As of 2026-11-05, DexCom(DXCM) stock has fluctuated between $84.24 and $88.96. The current price stands at $88.28, placing the stock +4.8% above today's low and -0.8% off the high.

The DexCom(DXCM)'s current trading volume is 5.25M, compared to an average daily volume of 6.06M.

During the past year, DexCom(DXCM) stock moved between $54.11 at its lowest and $92.59 at its peak.

DXCM News

Simply Wall St 8h

DexCom Stock Has The Bull Case Changed After The Canada Launch And Guidance Raise

DexCom reported third quarter 2026 sales of US$1.34b with stable basic EPS from continuing operations, raised full year revenue guidance, and announced a US$1b...

Simply Wall St 2d

Why DexCom Could Be 28% Below Fair Value Following Raised 2026 Guidance

DexCom (DXCM) is back in focus after Q3 results topped Wall Street expectations, management raised full year 2026 revenue guidance to a range of US$5.20b to US$...

Simply Wall St 5d

DexCom Stock Price Trails Stronger Q3 Earnings Momentum

Dexcom just reported Q3 2026 results with a clear beat on the key factor in diabetes technology profitability, while the stock moved only 3% higher to about US$...

Analyst ratings

84%

of 32 ratings

Buy

84.4%

Hold

15.6%

Sell

More DXCM News

Simply Wall St 5d

DexCom Stock Could Be 41% Undervalued As Guidance Rises

has delivered strong recent gains, yet its longer term record is mixed, which puts the spotlight on whether today's share price is backed by the cash the busine...

Zacks 6d

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise

DexCom, Inc. (DXCM Quick QuoteDXCM - Free Report) reported third-quarter 2026 adjusted earnings per share (EPS) of 73 cents, which beat the Zacks Consensu...

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.